JP2020535134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535134A5 JP2020535134A5 JP2020516599A JP2020516599A JP2020535134A5 JP 2020535134 A5 JP2020535134 A5 JP 2020535134A5 JP 2020516599 A JP2020516599 A JP 2020516599A JP 2020516599 A JP2020516599 A JP 2020516599A JP 2020535134 A5 JP2020535134 A5 JP 2020535134A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- disorder
- renal
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CN(C(C1)*1N1*)C1=O Chemical compound CN(C(C1)*1N1*)C1=O 0.000 description 3
- ZVXZRVYHSMZJKY-UHFFFAOYSA-N CC(CC1(C)N)CN(C)C1=O Chemical compound CC(CC1(C)N)CN(C)C1=O ZVXZRVYHSMZJKY-UHFFFAOYSA-N 0.000 description 1
- NSIGTHWDJCYZDR-UHFFFAOYSA-N CN(C(C1)C1C1)S1(=O)=O Chemical compound CN(C(C1)C1C1)S1(=O)=O NSIGTHWDJCYZDR-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023081938A JP7699626B2 (ja) | 2017-09-26 | 2023-05-18 | ラパマイシン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563312P | 2017-09-26 | 2017-09-26 | |
| US62/563,312 | 2017-09-26 | ||
| PCT/IB2018/057422 WO2019064182A1 (en) | 2017-09-26 | 2018-09-25 | RAPAMYCIN DERIVATIVES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023081938A Division JP7699626B2 (ja) | 2017-09-26 | 2023-05-18 | ラパマイシン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535134A JP2020535134A (ja) | 2020-12-03 |
| JP2020535134A5 true JP2020535134A5 (enExample) | 2021-10-14 |
| JP7387590B2 JP7387590B2 (ja) | 2023-11-28 |
Family
ID=63857991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516599A Active JP7387590B2 (ja) | 2017-09-26 | 2018-09-25 | ラパマイシン誘導体 |
| JP2023081938A Active JP7699626B2 (ja) | 2017-09-26 | 2023-05-18 | ラパマイシン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023081938A Active JP7699626B2 (ja) | 2017-09-26 | 2023-05-18 | ラパマイシン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10800793B2 (enExample) |
| EP (2) | EP4365179A3 (enExample) |
| JP (2) | JP7387590B2 (enExample) |
| KR (2) | KR20250054121A (enExample) |
| CN (2) | CN117417351A (enExample) |
| AR (1) | AR112834A1 (enExample) |
| AU (1) | AU2018342784B2 (enExample) |
| BR (1) | BR112020005898A2 (enExample) |
| CA (1) | CA3078191A1 (enExample) |
| DK (1) | DK3687999T3 (enExample) |
| ES (1) | ES2973975T3 (enExample) |
| FI (1) | FI3687999T3 (enExample) |
| HR (1) | HRP20240199T8 (enExample) |
| HU (1) | HUE065692T2 (enExample) |
| LT (1) | LT3687999T (enExample) |
| MX (2) | MX2020007265A (enExample) |
| PL (1) | PL3687999T3 (enExample) |
| PT (1) | PT3687999T (enExample) |
| RS (1) | RS65270B1 (enExample) |
| SI (1) | SI3687999T1 (enExample) |
| TW (1) | TW201920189A (enExample) |
| UY (1) | UY37900A (enExample) |
| WO (1) | WO2019064182A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| MX2018009408A (es) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. |
| CN108697701B (zh) | 2016-02-04 | 2021-10-26 | 约翰霍普金斯大学 | 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途 |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| BR112020022201A2 (pt) * | 2018-05-01 | 2021-02-02 | Revolution Medicines, Inc. | análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor |
| IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C-26-linked rapamycin analogs as MTOR inhibitors |
| IL279329B2 (en) | 2018-06-15 | 2025-01-01 | Navitor Pharm Inc | Rapamycin analogs and their uses |
| LT3898637T (lt) | 2018-12-18 | 2025-03-10 | Novartis Ag | Rapamicino dariniai |
| KR102643707B1 (ko) | 2019-01-22 | 2024-03-04 | 에오비안 파마슈티컬스, 인크. | Mtorc 조절제 및 이의 용도 |
| HRP20240633T1 (hr) * | 2019-03-26 | 2024-08-02 | Novartis Ag | Izotiazolidin 1,1-dioksid i 1,4-butan sulton derivati rapamicina i njihova uporaba |
| KR102486721B1 (ko) * | 2019-08-23 | 2023-01-10 | 이화여자대학교 산학협력단 | 신규 mTOR 억제제 화합물 및 이의 용도 |
| KR102497821B1 (ko) * | 2019-08-23 | 2023-02-08 | 이화여자대학교 산학협력단 | 신규 mTOR 억제제 화합물 및 이의 용도 |
| TW202126323A (zh) * | 2019-10-01 | 2021-07-16 | 約翰斯赫普金斯大學 | 雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法 |
| JP2023506410A (ja) | 2019-12-05 | 2023-02-16 | アナクリア セラピューティクス， インコーポレイテッド | ラパマイシン類似体及びその使用 |
| DE102020203224A1 (de) | 2020-03-12 | 2021-09-16 | Heinrich-Heine-Universität Düsseldorf | Inhibition von FKBP1A zur Therapie des Triple-negativen Mammakarzinoms |
| WO2021180840A1 (de) | 2020-03-12 | 2021-09-16 | Heinrich-Heine-Universität Düsseldorf | Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms |
| MX2022011964A (es) * | 2020-03-27 | 2022-12-02 | Aeovian Pharmaceuticals Inc | Moduladores de mtorc1 y usos de los mismos. |
| WO2022020522A2 (en) * | 2020-07-21 | 2022-01-27 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
| TW202206093A (zh) * | 2020-08-12 | 2022-02-16 | 中國醫藥大學 | Ｓｅｍａ３ｄ拮抗劑用於預防或治療神經退化性疾病以及延長壽命之用途 |
| CN119604293A (zh) | 2022-05-25 | 2025-03-11 | 锐新医药公司 | 用mTOR抑制剂治疗癌症的方法 |
| AU2024242998A1 (en) * | 2023-04-07 | 2025-10-23 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
| WO2024243449A1 (en) * | 2023-05-23 | 2024-11-28 | Tornado Therapeutics, Inc. | Rapamycin derivatives and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| DE69637641D1 (de) | 1995-06-07 | 2008-09-25 | Ariad Gene Therapeutics Inc | Auf rapamycin basierende regulation biologischer vorgänge |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| KR100400620B1 (ko) * | 1995-06-09 | 2004-02-18 | 노파르티스 아게 | 라파마이신유도체 |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| EP1045915A2 (en) | 1998-01-15 | 2000-10-25 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| ES2219388T3 (es) | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-epi-rapalogos. |
| LT3351246T (lt) | 2001-02-19 | 2019-07-10 | Novartis Pharma Ag | Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui |
| KR100956195B1 (ko) | 2002-02-01 | 2010-05-06 | 어리어드 파마슈티칼스, 인코포레이티드 | 인 함유 화합물 및 이의 용도 |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| GB0601406D0 (en) | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| WO2008022256A2 (en) | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| GB0911888D0 (en) * | 2009-07-08 | 2009-08-19 | Oxford Biodynamics Ltd | Method of treating age related disorders |
| WO2011123524A2 (en) * | 2010-03-31 | 2011-10-06 | Auspex Pharmaceutical, Inc. | Macrolide inhibitors of mtor |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| EP4230631A3 (en) | 2011-02-04 | 2024-03-27 | Synthon B.V. | Process for making trisubstituted silyloxyethyl triflates |
| EP2675450B1 (en) | 2011-02-16 | 2016-02-10 | Novartis AG | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| SG11201909924VA (en) | 2017-05-02 | 2019-11-28 | Revolution Medicines Inc | Rapamycin analogs as mtor inhibitors |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| LT3898637T (lt) | 2018-12-18 | 2025-03-10 | Novartis Ag | Rapamicino dariniai |
| HRP20240633T1 (hr) | 2019-03-26 | 2024-08-02 | Novartis Ag | Izotiazolidin 1,1-dioksid i 1,4-butan sulton derivati rapamicina i njihova uporaba |
-
2018
- 2018-09-24 UY UY0001037900A patent/UY37900A/es not_active Application Discontinuation
- 2018-09-24 AR ARP180102741A patent/AR112834A1/es unknown
- 2018-09-25 JP JP2020516599A patent/JP7387590B2/ja active Active
- 2018-09-25 KR KR1020257011373A patent/KR20250054121A/ko active Pending
- 2018-09-25 HU HUE18786408A patent/HUE065692T2/hu unknown
- 2018-09-25 AU AU2018342784A patent/AU2018342784B2/en active Active
- 2018-09-25 HR HRP20240199TT patent/HRP20240199T8/hr unknown
- 2018-09-25 CN CN202311329093.8A patent/CN117417351A/zh active Pending
- 2018-09-25 PL PL18786408.7T patent/PL3687999T3/pl unknown
- 2018-09-25 BR BR112020005898-0A patent/BR112020005898A2/pt unknown
- 2018-09-25 FI FIEP18786408.7T patent/FI3687999T3/fi active
- 2018-09-25 EP EP24150040.4A patent/EP4365179A3/en active Pending
- 2018-09-25 DK DK18786408.7T patent/DK3687999T3/da active
- 2018-09-25 US US16/141,856 patent/US10800793B2/en active Active
- 2018-09-25 PT PT187864087T patent/PT3687999T/pt unknown
- 2018-09-25 KR KR1020207007749A patent/KR102794731B1/ko active Active
- 2018-09-25 ES ES18786408T patent/ES2973975T3/es active Active
- 2018-09-25 CN CN201880057805.6A patent/CN111094299B/zh active Active
- 2018-09-25 EP EP18786408.7A patent/EP3687999B1/en active Active
- 2018-09-25 TW TW107133541A patent/TW201920189A/zh unknown
- 2018-09-25 LT LTEPPCT/IB2018/057422T patent/LT3687999T/lt unknown
- 2018-09-25 WO PCT/IB2018/057422 patent/WO2019064182A1/en not_active Ceased
- 2018-09-25 MX MX2020007265A patent/MX2020007265A/es unknown
- 2018-09-25 SI SI201831063T patent/SI3687999T1/sl unknown
- 2018-09-25 CA CA3078191A patent/CA3078191A1/en active Pending
- 2018-09-25 RS RS20240184A patent/RS65270B1/sr unknown
-
2020
- 2020-07-13 MX MX2023001876A patent/MX2023001876A/es unknown
- 2020-08-27 US US17/004,434 patent/US20200392159A1/en not_active Abandoned
-
2021
- 2021-10-12 US US17/499,433 patent/US12091424B2/en active Active
-
2023
- 2023-05-18 JP JP2023081938A patent/JP7699626B2/ja active Active
-
2024
- 2024-08-09 US US18/799,328 patent/US20250223297A1/en active Pending